EPITOPE SUMMARY
SLLMWITQC is a linear peptidic epitope (epitope ID
59278
) studied as part of Cancer/testis antigen 1 (UniProt:P78358) from Homo sapiens (human) and Isoform LAGE-1A of Cancer/testis antigen 2 (UniProt:O75638-2) from Homo sapiens (human). This epitope has been studied for immune reactivity in
74
publication(s), tested in
448
T cell assays,
8
B cell assays,
17
MHC ligand assays and has 3D structure(s)
2P5W
,
2P5E
,
2F53
,
2F54
,
2BNR
,
1S9W
and
2PYE
.
CURATED EXPERIMENTAL DATA
MHC Ligand Assay(s)
17
MHC moleculePositive / All
HLA-A*02:01
15
/
15
HLA-A2
2
/
2
B Cell Assay(s)
8
Assay TypePositive / All
secondary in vitro activity
3
/
3
dissociation constant KD
2
/
2
tumor burden after challenge after adoptive transfer
2
/
2
qualitative binding
1
/
1
T Cell Assay(s)
448
Assay TypePositive / All
IFNg release
69
/
71
qualitative binding
60
/
65
off rate
47
/
48
cytotoxicity
46
/
47
dissociation constant KD
46
/
47
on rate
38
/
39
TNFa release
15
/
15
IL-2 release
13
/
14
activation
12
/
13
binding constant
11
/
11
3D structure
7
/
7
CCL4/MIP-1b release
7
/
7
proliferation
7
/
7
tumor burden after challenge after adoptive transfer
7
/
7
decreased disease after adoptive transfer
5
/
6
T cell- APC binding
5
/
5
granzyme B release
4
/
4
degranulation
3
/
3
IL-13 release
3
/
3
IL-1b release
3
/
3
IL-4 release
3
/
3
IL-8 release
3
/
3
survival after tumor challenge after adoptive transfer
3
/
3
decreased disease
2
/
2
IL-10 release
2
/
2
IL-5 release
2
/
2
perforin release
2
/
2
TNF release
2
/
2
CCL3/MIP-1a release
1
/
1
CCL5/RANTES release
1
/
1
CXCL9/MIG release
1
/
1
GM-CSF release
1
/
1
protection from tumor challenge after adoptive transfer
1
/
1
survival from challenge
1
/
1
type IV hypersensitivity (DTH)
1
/
1
EXTERNAL RESOURCES
ResourceLink
IEDB-AR: MHC-I Processing
Predict MHC class I processing
IEDB-AR: MHC-I
Predict MHC class I binding affinity
IEDB-AR: B cell scales
Predict B cell epitopes